PepGen Inc. (PEPG)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PepGen Inc. (PEPG) trades at $1.76 with AI Score 27/100 (Grade F). PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Market cap: $121.74M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026PEPG stock analysis for 2026: Analysts have set a consensus price target of $7.00 for PepGen Inc., suggesting 297.7% upside from the current price of $1.76. The AI MoonshotScore is 27/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
PEPG: 1/1 perspectives are bearish.
How is this calculated? →PepGen Inc. (PEPG) Healthcare & Pipeline Overview
PepGen Inc. is a clinical-stage biotechnology company specializing in oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Their lead candidate, PGN-EDO51, targets Duchenne muscular dystrophy (DMD) and is currently in Phase I trials, positioning them in a competitive landscape focused on genetic medicines.
What Is the Investment Thesis for PEPG?
PepGen Inc. presents a focused investment opportunity within the biotechnology sector, specifically in the area of oligonucleotide therapeutics for neuromuscular and neurologic diseases. The primary value driver is the clinical progress of PGN-EDO51, their lead candidate for Duchenne muscular dystrophy (DMD), currently in Phase I trials. Positive clinical data could significantly increase the company's valuation. Further potential lies in the development of PGN-EDODM1 for myotonic dystrophy type 1 (DM1) and other pipeline candidates. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from other companies developing therapies for the same indications. With a market cap of $121.74M and a beta of 2.34, PEPG represents a high-risk, high-reward investment profile.
Based on FMP financials and quantitative analysis
PEPG Key Highlights
- PGN-EDO51, PepGen's lead product candidate, is currently in Phase I clinical trials for the treatment of Duchenne muscular dystrophy (DMD).
- PepGen is developing PGN-EDODM1 for the treatment of myotonic dystrophy type 1 (DM1), expanding their therapeutic pipeline.
- The company's technology focuses on Enhanced Delivery Oligonucleotides (EDOs) to improve the efficacy and safety of oligonucleotide-based therapies.
- PepGen was founded in 2018, indicating a relatively young company in the competitive biotechnology landscape.
- The company's market capitalization is $0.12 billion as of May 9, 2026.
Who Are PEPG's Competitors?
PEPG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SRPT Sarepta Therapeutics | $19.28 | +5.93% | $2.04B | 39 |
| BIIB Biogen Inc. | $216.12 | +3.04% | $31.91B | 78 |
| ANAB AnaptysBio, Inc. | $63.42 | -3.07% | $2.73B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $21.82 | +4.45% | $1.93B | 79 |
| CGEN Compugen Ltd. | $2.28 | +7.04% | $215.58M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.13 | +1.10% | $389.54M | 76 |
| AXSM Axsome Therapeutics, Inc. | $244.31 | +1.52% | $12.57B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PEPG's Key Strengths?
- Proprietary EDO technology platform enhances drug delivery.
- Lead product candidate PGN-EDO51 in Phase I clinical trials for DMD.
- Experienced management team with expertise in oligonucleotide therapeutics.
- Focus on addressing unmet medical needs in rare neuromuscular diseases.
What Are PEPG's Weaknesses?
- Clinical-stage company with no currently approved products.
- High cash burn rate associated with clinical development activities.
- Reliance on the success of a limited number of pipeline candidates.
- Small market capitalization, making it vulnerable to market fluctuations.
What Could Drive PEPG Stock Higher?
- Announcement of Phase I clinical trial results for PGN-EDO51 in DMD patients.
- Initiation of clinical trials for PGN-EDODM1 in myotonic dystrophy type 1 (DM1).
- Progress in preclinical development of PGN-EDO53, PGN-EDO45, and PGN-EDO44 for DMD.
- Potential for strategic partnerships and collaborations to accelerate pipeline development.
What Are the Key Risks for PEPG?
- Financial-distress signal — its Altman Z-Score of -0.83 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-59.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays for PGN-EDO51 or other pipeline candidates.
- Competition from other companies developing therapies for DMD and DM1.
- Regulatory hurdles and potential rejection of drug candidates.
- High cash burn rate associated with clinical development activities.
- Reliance on the success of a limited number of pipeline candidates.
What Are the Growth Opportunities for PEPG?
- Expansion of the DMD Pipeline: PepGen has the opportunity to expand its DMD pipeline beyond PGN-EDO51. The company is developing PGN-EDO53, PGN-EDO45, and PGN-EDO44, all targeting different exon-skipping approaches for the treatment of DMD. Each of these candidates represents a distinct market opportunity within the broader DMD treatment landscape. Positive preclinical and clinical data from these programs could significantly increase PepGen's market value and attract partnerships. The timeline for these programs will depend on successful preclinical development and regulatory approvals, with potential for new clinical trials starting within the next 2-3 years.
- Advancement of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1): PGN-EDODM1 represents a significant growth opportunity for PepGen in the treatment of DM1. Successful development and commercialization of PGN-EDODM1 would expand PepGen's therapeutic focus beyond DMD and address a significant unmet medical need in DM1. The DM1 market is estimated to grow substantially over the next decade, driven by increased diagnosis and the development of targeted therapies. Clinical trials for PGN-EDODM1 are expected to progress over the next 3-5 years, potentially leading to regulatory approval and market launch.
- Strategic Partnerships and Collaborations: PepGen can leverage strategic partnerships and collaborations to accelerate the development and commercialization of its pipeline candidates. Partnering with larger pharmaceutical companies or specialized biotechnology firms could provide access to additional resources, expertise, and funding. These collaborations can also help PepGen expand its geographic reach and market access. Potential partnership opportunities could arise within the next 1-2 years as PepGen's clinical programs advance and generate more data.
- Expansion into New Therapeutic Areas: While PepGen's initial focus is on neuromuscular and neurologic diseases, the company's EDO platform has the potential to be applied to other therapeutic areas. Expanding into new areas, such as oncology or rare genetic disorders, could significantly broaden PepGen's market opportunity and diversify its pipeline. This expansion would require additional research and development efforts, but could yield substantial long-term growth. The timeline for entering new therapeutic areas is likely 3-5 years, contingent on successful preclinical studies and proof-of-concept data.
- Geographic Expansion: PepGen currently operates primarily in the United States. Expanding into international markets, such as Europe and Asia, represents a significant growth opportunity. These markets offer access to a larger patient population and potentially faster regulatory pathways in some regions. Establishing a presence in these markets would require strategic planning, regulatory approvals, and partnerships with local distributors. The timeline for geographic expansion is estimated at 2-4 years, depending on regulatory requirements and market entry strategies.
What Opportunities Does PEPG Have?
- Positive clinical trial results for PGN-EDO51 and other pipeline candidates.
- Expansion into new therapeutic areas beyond neuromuscular diseases.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Potential for orphan drug designation and accelerated regulatory pathways.
What Threats Does PEPG Face?
- Clinical trial failures or delays.
- Competition from other companies developing therapies for DMD and DM1.
- Regulatory hurdles and potential rejection of drug candidates.
- Patent challenges or infringement claims.
What Are PEPG's Competitive Advantages?
- Proprietary EDO (Enhanced Delivery Oligonucleotide) technology platform.
- Strong intellectual property portfolio protecting their drug candidates and technologies.
- Clinical-stage pipeline with lead candidate PGN-EDO51 in Phase I trials.
- Expertise in oligonucleotide chemistry and drug development.
- Focus on addressing unmet medical needs in rare neuromuscular and neurologic diseases.
What Does PEPG Do?
Founded in 2018 and headquartered in Cambridge, Massachusetts, PepGen Inc. is dedicated to developing innovative oligonucleotide therapeutics aimed at treating severe neuromuscular and neurologic diseases. The company's core technology revolves around Enhanced Delivery Oligonucleotides (EDOs), which are designed to improve the efficacy and safety of oligonucleotide-based therapies. PepGen's lead product candidate, PGN-EDO51, is an EDO peptide currently undergoing Phase I clinical trials for the treatment of Duchenne muscular dystrophy (DMD). DMD is a genetic disorder characterized by progressive muscle degeneration and weakness due to alterations of the dystrophin protein. Beyond PGN-EDO51, PepGen is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1 (DM1), a disease characterized by muscle weakness, myotonia (prolonged muscle contraction), and a variety of other symptoms. Additionally, the company is advancing a pipeline of other EDO therapeutic candidates, including PGN-EDO53, PGN-EDO45, and PGN-EDO44, all targeting different exon-skipping approaches for the treatment of DMD. PepGen's focus is on addressing the underlying genetic causes of these debilitating diseases through targeted therapies.
What Products and Services Does PEPG Offer?
- Develop oligonucleotide therapeutics for neuromuscular diseases.
- Focus on treating severe genetic disorders like Duchenne muscular dystrophy (DMD).
- Utilize Enhanced Delivery Oligonucleotides (EDOs) to improve drug efficacy.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Develop therapies targeting the underlying genetic causes of diseases.
- Advance a pipeline of EDO therapeutic candidates for DMD and other conditions.
- Research and develop innovative approaches to oligonucleotide-based therapies.
- Address unmet medical needs in the treatment of neuromuscular and neurologic disorders.
How Does PEPG Make Money?
- Develop and patent novel oligonucleotide therapeutics.
- Conduct preclinical and clinical research to validate drug candidates.
- Seek regulatory approval from agencies like the FDA.
- Potentially commercialize approved therapies directly or through partnerships.
- Generate revenue through product sales, licensing agreements, and collaborations.
What Industry Does PEPG Operate In?
PepGen Inc. operates within the competitive biotechnology industry, specifically targeting neuromuscular and neurologic diseases. The market for genetic therapies is experiencing rapid growth, driven by advancements in oligonucleotide technologies and a greater understanding of disease mechanisms. Competition includes companies developing similar therapies for DMD and DM1, such as Sarepta Therapeutics and Biogen. The success of PepGen depends on demonstrating the superior efficacy and safety of its EDO platform compared to existing and emerging treatments. The global market for Duchenne muscular dystrophy treatment is projected to reach billions of dollars by 2030, presenting a significant opportunity for PepGen.
Who Are PEPG's Key Customers?
- Patients with Duchenne muscular dystrophy (DMD).
- Patients with myotonic dystrophy type 1 (DM1).
- Healthcare providers who treat patients with neuromuscular diseases.
- Pharmaceutical companies interested in licensing or acquiring novel therapies.
- Research institutions and academic centers involved in clinical trials.
How PepGen Inc. Is Valued
PepGen Inc. carries a market capitalization of $121.74M, placing it in the micro-cap category. Relative to its peer group, PEPG's quantitative score of 27/100 is below the peer average of 70/100.
ROE -60%Key Financial Metrics
Return on equity for PepGen Inc. stands at -59.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -49.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -63.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 14.98 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -63.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
PepGen Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.83 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project PepGen Inc. revenue of about $37.5M for fiscal 2026, with EPS near $-1.11. The estimate reflects 7 contributing analysts.
PEPG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- PepGen's insider buying suggests those in the know see long-term value, mirroring situations like early Tesla believers who doubled down.
- Community buzz hints at growing optimism around their pipeline, similar to the excitement surrounding CRISPR stocks a few years back.
- Recent positive clinical trial updates, even early stage, are fueling positive market perception, like the initial enthusiasm for mRNA tech.
- The company's focus on a specific therapeutic area is being seen as a strength, making them a potential acquisition target, much like smaller biotechs acquired by larger players.
Bear Case
- Some insiders are selling shares, which could signal concerns about short-term prospects, reminiscent of pre-crash insider selling before the 2008 crisis.
- The community is expressing worries about potential regulatory hurdles, similar to the challenges faced by gene therapy companies.
- Market perception is sensitive to broader economic downturns, potentially impacting funding and partnerships, like the dot-com bubble burst.
- Concerns exist about the long-term efficacy and safety of their therapies, a common concern in the biotech sector, like the initial skepticism surrounding some novel drug classes.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
PEPG Latest News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
prnewswire.com · May 7, 2026
PEPG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PEPG.
Price Targets
Consensus target: $7.00
PEPG MoonshotScore
What does this score mean?
The MoonshotScore rates PEPG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest PepGen Inc. Analysis
Leadership: James G. McArthur
CEO
James G. McArthur serves as the CEO of PepGen Inc., bringing extensive experience in the biotechnology and pharmaceutical industries. His background includes leadership roles at various companies focused on drug development and commercialization. He has a proven track record of successfully guiding companies through clinical development and regulatory approval processes. McArthur's expertise spans areas such as strategic planning, business development, and financial management. He holds advanced degrees in relevant scientific disciplines, providing a strong foundation for his leadership in the biotechnology sector.
Track Record: Under James G. McArthur's leadership, PepGen Inc. has advanced its lead product candidate, PGN-EDO51, into Phase I clinical trials for Duchenne muscular dystrophy (DMD). He has overseen the expansion of the company's pipeline and the development of its proprietary EDO technology platform. McArthur has also been instrumental in securing funding and establishing strategic partnerships to support PepGen's growth.
Common Questions About PEPG (Healthcare)
What does PepGen Inc. do?
PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company's core technology revolves around Enhanced Delivery Oligonucleotides (EDOs), which are designed to improve the efficacy and safety of oligonucleotide-based therapies. Their lead product candidate, PGN-EDO51, is in Phase I clinical trials for Duchenne muscular dystrophy (DMD). PepGen aims to address the underlying genetic causes of these debilitating diseases through targeted therapies, offering potential solutions where limited options currently exist.
What do analysts say about PEPG stock?
Analyst coverage of PepGen Inc. is still emerging, given its clinical-stage nature and relatively recent founding. Current sentiment reflects a focus on the potential of their EDO technology and the progress of PGN-EDO51 in Phase I trials. Key valuation metrics are heavily influenced by the projected success of their pipeline and the market opportunity in DMD and DM1. Growth considerations center on clinical trial outcomes, regulatory milestones, and the company's ability to secure partnerships and funding to support its development programs. Investors should closely monitor clinical data releases and regulatory updates.
What are the main risks for PEPG?
PepGen Inc. faces several key risks inherent to clinical-stage biotechnology companies. The primary risk is the potential failure or delay of clinical trials for PGN-EDO51 and other pipeline candidates. Competition from established pharmaceutical companies and other biotechnology firms developing therapies for DMD and DM1 also poses a significant threat. Regulatory hurdles and the potential rejection of drug candidates by agencies like the FDA represent another major risk. Additionally, the company's high cash burn rate and reliance on a limited number of pipeline candidates create financial and operational vulnerabilities.
What are the key factors to evaluate for PEPG?
PepGen Inc. (PEPG) holds an AI score of 27/100 (low). Analysts target $7.00 (+298%). Not financial advice.
How frequently does PEPG data refresh on this page?
PEPG prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PEPG's recent stock price performance?
PepGen Inc. (PEPG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary EDO technology platform enhances drug delivery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PEPG overvalued or undervalued right now?
Valuing PepGen Inc. (PEPG) requires multiple metrics. Analysts target $7.00 (+298%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PEPG?
Before investing in PepGen Inc. (PEPG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Clinical trial outcomes are inherently uncertain and can impact company valuation.